Age-Related Macular Degeneration (ARMD) Clinical Trials

Find Age-Related Macular Degeneration (ARMD) Clinical Trials Near You

Find a DoctorCondition OverviewLatest AdvancesClinical TrialsTreatments

Analysis of Biomarkers From Patients With Chorioretinal Diseases

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY

This study was conducted to investigate the levels of ocular biomarkers from the patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Maximum Age: 80
Healthy Volunteers: t
View:

• age over 20 years

• patients requiring ophthalmologic treatments for different degrees of decreasing of visual acuity.

• patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration.

• control patients asking cataract surgery or vitrectomy for posterior segment nonproliferative disorders.

Locations
Other Locations
Republic of Korea
Dong Ho Park
RECRUITING
Daegu
Contact Information
Primary
Dong Ho Park, M.D.
sarasate2222@gmail.com
82-53-420-5813
Time Frame
Start Date: 2012-04
Estimated Completion Date: 2031-04
Participants
Target number of participants: 100
Treatments
Chorioretinal diseases
chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration.
Control
control patients with surgeries include pars plana vitrectomy of macular hole, epiretinal membrane, cataract surgery.
Related Therapeutic Areas
Late-Onset Retinal Degeneration
Geographic Atrophy
Age-Related Macular Degeneration (ARMD)
Diabetic Retinopathy
Sponsors
Leads: Kyungpook National University Hospital

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

Generation of Induced Pluripotent Stem (iPS) Cell Lines From Somatic Cells of Participants With Eye Diseases and From Somatic Cells of Matched Controls

Generation of Induced Pluripotent Stem (iPS) Cell Lines From Somatic Cells of Participants With Eye Diseases and From Somatic Cells of Matched Controls

Enrollment Status: Recruiting
Publish Date: October 07, 2025

The Effects of Disulfiram on Visual Acuity in Patients With Retinal Degeneration

The Effects of Disulfiram on Visual Acuity in Patients With Retinal Degeneration

Enrollment Status: Recruiting
Publish Date: September 29, 2025
Intervention Type: Drug
Study Phase: Phase 1

Safety and Efficacy of Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium in the Treatment of Macular Degeneration

Safety and Efficacy of Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium in the Treatment of Macular Degeneration

Enrollment Status: Recruiting
Publish Date: July 06, 2022
Intervention Type: Biological
Study Phase: Phase 1
View All
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved